JP2023543898A5 - - Google Patents
Info
- Publication number
- JP2023543898A5 JP2023543898A5 JP2023520059A JP2023520059A JP2023543898A5 JP 2023543898 A5 JP2023543898 A5 JP 2023543898A5 JP 2023520059 A JP2023520059 A JP 2023520059A JP 2023520059 A JP2023520059 A JP 2023520059A JP 2023543898 A5 JP2023543898 A5 JP 2023543898A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- shtg
- fpl
- fcs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087095P | 2020-10-02 | 2020-10-02 | |
| US63/087,095 | 2020-10-02 | ||
| PCT/US2021/052001 WO2022072244A1 (en) | 2020-10-02 | 2021-09-24 | Methods for reducing apociii expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023543898A JP2023543898A (ja) | 2023-10-18 |
| JP2023543898A5 true JP2023543898A5 (cg-RX-API-DMAC7.html) | 2024-10-02 |
| JP7891470B2 JP7891470B2 (ja) | 2026-07-16 |
Family
ID=80950871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520059A Active JP7891470B2 (ja) | 2020-10-02 | 2021-09-24 | Apociii発現を減少させるための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240033280A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4221720A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7891470B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230079394A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116348125A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021353849A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004012A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300882A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023003855A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022072244A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2023372971A1 (en) * | 2022-11-02 | 2025-05-15 | Ionis Pharmaceuticals, Inc. | Methods for modulating complement factor b expression |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| KR20200123263A (ko) * | 2013-02-14 | 2020-10-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절 |
| AU2016222548A1 (en) * | 2015-02-27 | 2017-07-27 | Ionis Pharmaceuticals, Inc. | Modulation of apolipoprotein C-III (ApoCIII) expression in lipodystrophy populations |
| LT4119569T (lt) * | 2015-11-06 | 2024-09-25 | Ionis Pharmaceuticals, Inc. | Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje |
-
2021
- 2021-09-24 CN CN202180066569.6A patent/CN116348125A/zh active Pending
- 2021-09-24 US US18/247,567 patent/US20240033280A1/en active Pending
- 2021-09-24 KR KR1020237013301A patent/KR20230079394A/ko active Pending
- 2021-09-24 WO PCT/US2021/052001 patent/WO2022072244A1/en not_active Ceased
- 2021-09-24 IL IL300882A patent/IL300882A/en unknown
- 2021-09-24 EP EP21876250.8A patent/EP4221720A4/en active Pending
- 2021-09-24 AU AU2021353849A patent/AU2021353849A1/en active Pending
- 2021-09-24 MX MX2023003855A patent/MX2023003855A/es unknown
- 2021-09-24 BR BR112023004012A patent/BR112023004012A2/pt unknown
- 2021-09-24 JP JP2023520059A patent/JP7891470B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| US10376533B2 (en) | Compositions and methods for treating viral infections | |
| JP2688113B2 (ja) | 多発性硬化症の治療のための置換アデニン誘導体を含む薬学的組成物 | |
| JP2019511491A5 (cg-RX-API-DMAC7.html) | ||
| JP2017532982A (ja) | Smad7アンチセンスオリゴヌクレオチドの同位体置換体 | |
| JP2026041749A5 (cg-RX-API-DMAC7.html) | ||
| JP2024037841A5 (cg-RX-API-DMAC7.html) | ||
| JP2018126141A5 (cg-RX-API-DMAC7.html) | ||
| BR112020018209A2 (pt) | Composições farmacêuticas, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e para tratar ou prevenir um coronavírus humano, coronavírus sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus da chicungunha, vírus ross river, rsv, vírus influenza a, vírus influenza b, vírus tacaribe, vírus pichinde, vírus junin, vírus da febre lassa, vírus da cariomeningite linfocitária, vírus da febre rift valley, vírus punta toro, vírus lacrosse, vírus maporal, vírus heartland, e vírus da síndrome de trombocitopenia de febre severa, poliovírus, vírus de coxsackie, infecção de norovírus ou enterovírus em um paciente | |
| JP2019088329A5 (cg-RX-API-DMAC7.html) | ||
| JP2002522552A (ja) | B型肝炎の治療のためのβ−L−2’−デオキシ−ヌクレオシド | |
| JP2018530325A5 (cg-RX-API-DMAC7.html) | ||
| ES2953535T3 (es) | Métodos de tratamiento y profilaxis del VIH y el sida | |
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| CN114533739A (zh) | 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用 | |
| JP2021511072A5 (cg-RX-API-DMAC7.html) | ||
| CN104955458A (zh) | 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法 | |
| JP2020528910A5 (cg-RX-API-DMAC7.html) | ||
| AU1350197A (en) | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase | |
| TW202604464A (zh) | 用於脂質奈米顆粒之galnac脂質化合物 | |
| JP2011515357A5 (cg-RX-API-DMAC7.html) | ||
| US20230025976A1 (en) | PRMT5 Inhibitor for Use In A Method of Treating Psoriasis and Other Autoimmune Conditions | |
| KR940010441B1 (ko) | B형감염의 항비루스제 | |
| US6432924B1 (en) | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase | |
| JP2025504017A5 (cg-RX-API-DMAC7.html) |